Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012599 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Zuxin Liang und 14 weiteren Autor:innen. Beteiligte Einrichtung: BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Med…. Hauptthemen laut MEDLINE: SARS-CoV-2, Polysaccharides, COVID-19 Vaccines, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research & Development Program of China, The Guangdong Basic and Applied Basic Research Foundation, Beijing Institute of Technology Research Fund Program for Young Scholars.
Abstract (Originalsprache)
Emerging and recurrent infectious diseases caused by coronaviruses remain a significant public health concern. Here, we present a targeted approach to elicit antibodies capable of neutralizing SARS-CoV-2 variants and other SARS-related coronaviruses. By introducing amino acid mutations at mutation-prone sites, we engineered glycosylation modifications to the Receptor Binding Domain (RBD) of SARS-CoV-2, thereby exposing more conserved, yet less accessible epitopes. We developed both messenger RNA (mRNA) and recombination subunit vaccines using these engineered-RBDs (M1, M2) and the wild-type RBD as immunogens. The engineered-RBD vaccines elicited robust neutralizing responses against various SARS-CoV-2 variants as well as SARS-CoV and WIV1-CoV, and conferred protection in mice challenged with the XBB.1.16 strain. Furthermore, We highlighted that glycan masking is a decisive factor in antibody binding changes and RBD-conserved antibody response. Additionally, the glycan-engineered RBD mRNA vaccines stimulated stronger cell-mediated immune responses. Our glycan modification strategy significantly enhances broad-spectrum neutralizing efficacy and cellular immunity, providing valuable insights for the development of vaccines against a wide range of SARS-related coronaviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital; Southern Medical University, Guangzhou, Peop…
- School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.
- National Clinical Research Center for infectious disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, People's Republic of China.
- Laboratory Animal Center, Anhui Medical University, Hefei, People's Republic of China.
- Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Ministry of Education, Guangzhou, People's Republic of China.
ORCID-Profile: Minghui Yang
Förderung
- National Key Research & Development Program of China
- The Guangdong Basic and Applied Basic Research Foundation
- Beijing Institute of Technology Research Fund Program for Young Scholars
- National Natural Science Foundation of China
- Guangdong Science and Technology Program key projects
Zitieren
APA
Liang, Z., Li, C., Gong, X., Ye, G., Jiang, Y., Shi, H., Hussain, A., Zhao, M., Li, M., Tian, Y., Zhao, W., Yang, Y., Huang, Y., Shen, C., & Yang, M. (2024). Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012599
Vancouver
Liang Z, Li C, Gong X, Ye G, Jiang Y, Shi H, et al. Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012599
BibTeX
@article{Liang2024,
author = {Liang, Zuxin and Li, Chunhui and Gong, Xiaohua and Ye, Guoguo and Jiang, Yushan and Shi, Huiping and Hussain, Abid and Zhao, Mengyuan and Li, Mengjun and Tian, Yuxin and Zhao, Wei and Yang, Yang and Huang, Yuanyu and Shen, Chenguang and Yang, Minghui},
title = {Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012599}
}
EUVIMED